Mostrar el registro sencillo del ítem

dc.contributor.authorHernández Hernández, Laura
dc.contributor.authorSanz Lozano, Catalina Sofía 
dc.contributor.authorMarcos-Vadillo, Elena
dc.contributor.authorGarcía Sánchez, María Asunción 
dc.contributor.authorMoreno Rodilla, Esther María 
dc.contributor.authorLorente Toledano, Félix
dc.contributor.authorGonzález-de-Olano, David
dc.contributor.authorDávila González, Ignacio Jesús 
dc.contributor.authorIsidoro García, María 
dc.date.accessioned2024-07-01T11:20:51Z
dc.date.available2024-07-01T11:20:51Z
dc.date.issued2021-04-13
dc.identifier.citationHernández-Hernández, L., Sanz, C., Marcos-Vadillo, E., García-Sánchez, A., Moreno, E., Lorente, F., González-de-Olano, D., Dávila, I., & Isidoro-García, M. (2021). Increased TPSAB1 Copy Number in a Family With Elevated Basal Serum Levels of Tryptase. Frontiers in Medicine, 8. https://doi.org/10.3389/FMED.2021.577081. PMID: 33928098; PMCID: PMC8076508.es_ES
dc.identifier.urihttp://hdl.handle.net/10366/158748
dc.description.abstract[EN]Background: Some recent familial studies have described a pattern of autosomal dominant inheritance for increased basal serum tryptase (BST), but no correlation with mRNA expression and gene dose have been reported. Objective: We analyzed TPSAB1 mRNA expression and gene dose in a four-member family with high BST and in two control subjects. Methods: Blood samples were collected from the family and control subjects. Complete morphologic, immunophenotypical, and molecular bone marrow mast cell (MC) studies were performed. mRNA gene expression and gene dose were performed in a LightCycler 480 instrument. Genotype and CNV were performed by quantitative real-time digital PCR (qdPCR). Results: CNV analysis revealed a hereditary copy number gain genotype (3β2α) present in all the family members studied. The elevated total BST in the family members correlated with a significant increase in tryptase gene expression and dose. Conclusions and Clinical Relevance: We present a family with hereditary α-tryptasemia and elevated BST which correlated with a high expression of tryptase genes and an increased gene dose. The family members presented with atypical MC-mediator release symptoms or were even asymptomatic. Clinicians should be aware that elevated BST does not always mean an MC disorder.en_EN
dc.description.sponsorshipSpanish Foundation of the Spanish Association of Allergy and Clinical Immunology (Sociedad Española de Alergologia e Inmunologia Clínica); the Council of Castilla y León; European Social Fund, the Immunoallergic Association of Salamanca; Asthma, Allergic, and Adverse Reactions networks for Cooperative Research in Health (ARADyAL); Instituto de Salud Carlos III; European Regional Development Fund (ERDF).es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaen_EN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBasal serum tryptaseen_EN
dc.subjectHereditary α-tryptasemiaen_EN
dc.subjectMast cellsen_EN
dc.subjectTryptaseen_EN
dc.subjectβ-tryptaseen_EN
dc.subject.meshGenetics *
dc.subject.meshAllergy and Immunology *
dc.titleIncreased TPSAB1 copy number in a family with elevated basal serum levels of tryptaseen_EN
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3389/fmed.2021.577081es_ES
dc.subject.unesco3207.01 Alergiases_ES
dc.subject.unesco2409 Genéticaes_ES
dc.identifier.doi10.3389/FMED.2021.577081
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid33928098
dc.identifier.essn2296-858X
dc.journal.titleFrontiers in Medicineen_EN
dc.volume.number8es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsalergia e inmunología *
dc.subject.decsgenética *


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional